more relaxed about liver testing for Actos and Avandia
September 2004
Experts are becoming more relaxed about liver testing for Actos and Avandia.
The concern stems from the related glitazone, Rezulin, which caused serious hepatotoxicity. The U.S. FDA took it off the market a few years ago. Health Canada, wisely, never even allowed it on the Canadian market.
Due to this scare, liver enzymes were recommended every 2 months for the first year for Actos (pioglitazone) and Avandia (rosiglitazone).
Practical advice for a better career, with unlimited access to CE
Pharmacy Technician's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 120+ CE courses, including the popular CE-in-the-Letter
- Helpful, in-depth Technician Tutorials
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote